Meeting
2014 ASCO Annual Meeting
Randomized phase III study of taxane versus TS-1 as first-line treatment for metastatic breast cancer (SELECT BC).
Authors
Fumikata Hara
NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan
Fumikata Hara , Nobuaki Matsubara , Tsuyoshi Saito , Toshimi Takano , Youngjin Park , Tatsuya Toyama , Yasuo Hozumi , Junji Tsurutani , Shigeru Imoto , Tsutomu Takashima , Takanori Watanabe , Yoshiaki Sagara , Reiki Nishimura , Yasuo Ohashi , Hirofumi Mukai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
C000000416
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1012)
DOI
10.1200/jco.2014.32.15_suppl.1012
Abstract #
1012
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG )MA.31/GSK EGF 108919).
First Author: W. Parulekar
Poster
2020 ASCO Virtual Scientific Program
The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) metastatic breast cancer (MBC).
First Author: Sudpreeda Chainitikun
Poster
2018 ASCO Annual Meeting
Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).
First Author: Wolfgang Janni
Poster
2017 ASCO Annual Meeting
A randomised phase 2 study of 3 weekly cabazitaxel vs weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer.
First Author: Amit Bahl